Tokyo, Japan

Yuichi Sugimoto


 

Average Co-Inventor Count = 6.4

ph-index = 2

Forward Citations = 92(Granted Patents)


Location History:

  • Tokyo, JP (2007 - 2010)
  • Kobe, JP (2013)

Company Filing History:


Years Active: 2007-2013

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yuichi Sugimoto: Innovator in Pharmaceutical Chemistry

Introduction

Yuichi Sugimoto is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 3 patents to his name, Sugimoto's work has the potential to impact various medical treatments.

Latest Patents

One of Sugimoto's latest patents is related to an Isoindolin-1-one derivative. This invention pertains to a compound represented by a specific formula, where various groups can represent hydrogen or halogen atoms, and other components are designed to enhance its pharmaceutical properties. Another notable patent involves antifungal bicyclic hetero ring compounds, which serve as a 1,6-β-glucan synthetase inhibitor. This compound demonstrates potent growth inhibition and excellent safety, making it a promising candidate for antifungal treatments.

Career Highlights

Throughout his career, Yuichi Sugimoto has worked with esteemed companies such as Daiichi Pharmaceutical Co., Ltd. and Daiichi Sankyo Company, Limited. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Sugimoto has collaborated with notable colleagues, including Atsushi Nakayama and Nobuo Machinaga. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

In summary, Yuichi Sugimoto is a distinguished inventor whose work in pharmaceutical chemistry has led to the development of innovative compounds with significant therapeutic potential. His contributions continue to shape the landscape of medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…